Li‐Fan Zeng
Papers
1
Total Citations
39
H-Index
1
About
Dr. Li‐Fan Zeng is a distinguished chemical biologist whose research centers on the development of innovative high-throughput screening technologies to discover small-molecule inhibitors of protein arginine methyltransferases (PRMTs). His seminal work, "Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases" (2017, 39 citations), introduced a robust, sensitive assay that enables rapid identification of PRMT modulators. This contribution is pivotal because PRMTs—a family of nine enzymes that catalyze arginine methylation of histone and non-histone proteins—play critical roles in regulating gene expression, signal transduction, and cellular differentiation. By providing a scalable platform for inhibitor discovery, Dr. Zeng’s research directly advances the development of targeted therapeutics for cancers and other diseases driven by aberrant PRMT activity. His work bridges fundamental enzymology and translational drug discovery, offering powerful tools for both academic labs and pharmaceutical pipelines. Dr. Zeng’s impact is reflected in the continued adoption of his AlphaLISA method, which has become a cornerstone for PRMT inhibitor screening worldwide.
Research Focus
Key Achievements
Top Papers
- 1